UCB

success failure signposts
Biotech

UCB's tau drug flunks Alzheimer's trial days after Roche's exit

UCB looked past the primary endpoint miss and focused on other results that left it “deeply encouraged” by the trial.
Nick Paul Taylor Nov 1, 2024 6:01am
arrow back backwards u-turn turn around reverse

Roche tosses out $120M tau prospect, returning rights to UCB

Oct 22, 2024 8:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Biogen, UCB report phase 3 lupus win after failing earlier trial

Sep 24, 2024 6:00am
ringing alarm clock times up

100 days with John Crowley: Behind BIO’s new structure & vision

Jun 25, 2024 9:05am
Handshake

Veeva, UCB link to leverage digital tools in clinical trials

May 24, 2023 3:25pm
graphic of the brain and the electrical signals that make it up

Praxis ends year on high with $100M biobucks UCB deal

Dec 14, 2022 5:29am